General Electric Company

Eric Dustin Agdeppa

Michael Christopher Montalto

Cristina Tan Hehir

Tiberiu Mircea Siclovan

Kenneth Michael Fish

Srabani Bhaumik

Jeannette Christine DePuy

June Klimash

Anton Beletskii

Amy Casey Williams

Tun Chiao Hubert Lam

Provided herein are methods for imaging an optically labeled target cell implanted in vivo using a reporter construct that encodes an enzyme that is not endogenous to the target cell. The disclosed methods include the steps of: (a) introducing target cell transformed with non-endogenous enzyme into a mammalian subject; (b) contacting the transformed target cell with a cell-permeable soluble fluorescent dye; and (c) observing a fluorescent signal generated by the target cell present in the mammalian subject. In some embodiments, the non-endogenous enzyme comprises a nitroreductase. In some embodiments, the methods may also include the step of tracking the fluorescent target cells in the mammalian subject over time.

In vivo optical imaging

Provided herein are methods of monitoring inflammatory cell migration in a mammal. The methods include the steps of: providing a donor mammalian subject; introducing an inflammatory agent into the donor mammal to create a granuloma; isolating granuloma-derived nucleated cells from the granuloma of the donor mammalian subject; labeling the granuloma-derived nucleated cells with an optical agent; providing a recipient mammalian subject with inflamed tissue; introducing the granuloma-derived nucleated cells into a recipient mammalian subject at a site remote from site where the inflammatory agent was introduced; and imaging the recipient mammalian subject using an optical system. The methods may also include analysing the distribution of the labeled granuloma-derived cells in the recipient mammal.

In vivo cell trafficking

Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.

Methods for imaging soluble A-beta

Provided herein are amyloid-binding assays that simulate in situ brain conditions by combining binders with various A-beta species on mammalian brain tissue. In general the amyloid-binding assays comprise the steps of (a) contacting a mammalian brain tissue sample with at least one A-beta species; (b) applying a putative binder to the brain tissue sample; and (c) determining whether the putative binder binds to the A-beta species.

Amyloid binding assays

Agents for imaging soluble a-beta

Growing community of inventors

Fairview, NJ, United States of America

Eric Dustin Agdeppa